Suche
Mein Konto
Revolutionary cancer vaccination: New research center opened in Vienna!
Vaccentis will open a biotech research center in Vienna's Seestadt in 2025, focused on the cancer vaccination VCC-001 for EU approval.
Revolutionary cancer vaccination: New research center opened in Vienna!
An exciting chapter in biotechnology begins in Seestadt Vienna! The Swiss company Vaccentis has opened its new EU research center, which will in future function as a central competence center for research and development activities and regulatory tasks. With this step, Vaccentis underlines its ambition to bring the therapeutic cancer vaccine VCC-001 to market more quickly and efficiently.
Ingrid Rauter, Head of Research at Vaccentis, highlights how important this expansion is for the development of European approval programs. “Vienna acts as a strategic bridgehead in the EU to bring innovations to patients more quickly,” she explains. The research center is particularly focused on preparations for approval of the vaccine by the European Medicines Agency (EMA), which is based in Amsterdam and plays a key role in the regulation of medicines in Europe. The EMA ensures that medicines undergo rigorous scientific evaluation and are safe before entering the market, as described in the official Here.
VCC-001: An individual approach to cancer therapy
The vaccine VCC-001, which is developed from patients' own tissue, represents an innovative approach in individualized medicine. It is currently being developed primarily for the adjuvant treatment of renal cell carcinoma, although further indications are also being planned. Previous clinical studies have already shown promising results, both in terms of effectiveness and side effect profile, which have a positive impact on patients' quality of life. Vaccentis plans to submit regulatory submissions for VCC-001 to the EMA, the US Food and Drug Administration (FDA) and Swissmedic by the end of the decade.
Based in Zurich, the company, which specializes in the development of individual cancer vaccines, remains a central player in the global biotech landscape, but is now also conducting its research activities in Vienna. This expansion is not only a sign of the company's growth, but also of Vienna's attractiveness as a biotech location.
Strategic investments and future plans
Vaccentis plans to expand its investments in Austria to further advance the development of VCC-001. These measures are intended to ensure that the innovative therapies are made accessible not only in the EU but also internationally. “We have a good knack for the next steps,” says Rauter, “and we are convinced that our location in Vienna offers a decisive advantage.” This is a significant step for future healthcare, as access to innovative therapies will become a reality for many patients.
The opening of the new location in Vienna is not only significant progress for Vaccentis, but also for the entire biotech industry in Austria, which is increasingly establishing itself as a hotspot for research and development. The excitement surrounding the new research center shows once again that there is a lot of movement in the Seestadt and big things are being prepared.